The use of everolimus in renal-transplant patients

Area of Science:

• Nephrology
• Immunosuppression
• Transplantation immunology

Background:

• Long-term renal transplant outcomes remain suboptimal despite immunosuppressive therapy advances.
• Calcineurin inhibitor (CNI) nephrotoxicity is a primary cause of chronic allograft nephropathy (CAN) and graft loss.
• Everolimus, a proliferation signal inhibitor, offers a distinct mechanism of action from CNIs.

Purpose of the Study:

• To evaluate the role of everolimus in improving renal transplant outcomes.
• To explore the synergistic effects of everolimus with reduced CNI doses.
• To assess the potential of everolimus in preventing CAN progression.

Main Methods:

• Investigating everolimus in combination with cyclosporine (CsA) to allow CsA dose reduction.
• Examining everolimus-containing regimens with reduced CNI exposure from the early post-transplant period.
• Assessing the impact of everolimus on smooth muscle cell proliferation and CAN development.

Main Results:

• Synergism between everolimus and CsA enables CsA dose reduction, minimizing nephrotoxicity without compromising efficacy.
• Everolimus may delay CAN progression by inhibiting smooth muscle cell proliferation.
• Clinical trials establish the efficacy and tolerability of everolimus in renal transplant recipients.

Conclusions:

• Everolimus plays a key role in renal transplantation by targeting major causes of graft loss.
• Reduced CNI exposure regimens with everolimus are being investigated to improve renal function and prevent CAN.
• Ongoing trials (Phase III-IV) further explore the potential of everolimus in renal transplantation.